Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 94 (1) , 111-120.e3
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 23 references indexed in Scilit:
- The effect of selective gut stimulation on glucose metabolism after gastric bypass in the Zucker diabetic fatty rat modelSurgery for Obesity and Related Diseases, 2014
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfactionPrimary Care Diabetes, 2012
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- In vivo characterization of the liver fat 1H MR spectrumNMR in Biomedicine, 2010
- Exenatide therapy in insulin-treated type 2 diabetes and obesityQJM: An International Journal of Medicine, 2010
- The Effect of Oral Antidiabetic Agents on A1C LevelsDiabetes Care, 2010
- Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 SecretionDiabetes Care, 2009
- Management of the Metabolic Syndrome and Type 2 Diabetes Through Lifestyle ModificationAnnual Review of Nutrition, 2009
- Type 2 Diabetes Prevention in the “Real World”Diabetes Care, 2007